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A B S T R A C T
Background: Natural killer T (NKT) cells in adipose tissue (AT) contribute to whole body energy homeostasis.
Results: Inhibition of the glucosylceramide synthesis in adipocytes impairs iNKT cell activity.
Conclusion: Glucosylceramide biosynthesis pathway is important for endogenous lipid antigen activation of
iNKT cells in adipocytes.
Significance: Unraveling adipocyte-iNKT cell communication may help to fight obesity-induced AT dysfunction.
Overproduction and/or accumulation of ceramide and ceramide metabolites, including glucosylceramides,
can lead to insulin resistance. However, glucosylceramides also fulfill important physiological functions. They
are presented by antigen presenting cells (APC) as endogenous lipid antigens via CD1d to activate a unique
lymphocyte subspecies, the CD1d-restricted invariant (i) natural killer T (NKT) cells. Recently, adipocytes have
emerged as lipid APC that can activate adipose tissue-resident iNKT cells and thereby contribute to whole body
energy homeostasis. Here we investigate the role of the glucosylceramide biosynthesis pathway in the activation
of iNKT cells by adipocytes.
UDP-glucose ceramide glucosyltransferase (Ugcg), the first rate limiting step in the glucosylceramide bio-
synthesis pathway, was inhibited via chemical compounds and shRNA knockdown in vivo and in vitro. β-1,4-
Galactosyltransferase (B4Galt) 5 and 6, enzymes that convert glucosylceramides into potentially inactive lac-
tosylceramides, were subjected to shRNA knock down. Subsequently, (pre)adipocyte cell lines were tested in co-
culture experiments with iNKT cells (IFNγ and IL4 secretion).
Inhibition of Ugcg activity shows that it regulates presentation of a considerable fraction of lipid self-antigens
in adipocytes. Furthermore, reduced expression levels of either B4Galt5 or -6, indicate that B4Galt5 is dominant
in the production of cellular lactosylceramides, but that inhibition of either enzyme results in increased iNKT cell
activation. Additionally, in vivo inhibition of Ugcg by the aminosugar AMP-DNM results in decreased iNKT cell
effector function in adipose tissue.
Inhibition of endogenous glucosylceramide production results in decreased iNKT cells activity and cytokine
production, underscoring the role of this biosynthetic pathway in lipid self-antigen presentation by adipocytes.
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1. Introduction
Adipose tissue (AT), a site where the immune system and metabolic
pathways intersect, undergoes marked changes during the progression
of obesity [1,2]. Adipocyte hypertrophy and hyperplasia contribute to
adipocyte dysfunction, which in turn promotes an infiltration of
proinflammatory immune cells. The pro-inflammatory state of AT is
characterized by inflammasome activation, increased release of free
fatty acids (FFAs) and cytokines [3,4]. In addition, lipid overloading of
the adipocytes results in accumulation of ceramide and ceramide me-
tabolites, including glucosylceramides, which, together with the pro-
inflammatory state of AT result in impaired insulin receptor signaling
and metabolic derangements [5–7].
While clearly implicated in the pathophysiological consequences of
obesity, ceramide metabolites also serve physiological functions. For
example, exogenous and endogenous glycosylceramides including glu-
cosylceramides (GluCer) and galactosylceramides (GalCer), can be
displayed by APC in an immunogenic fashion that can activate a unique
subset of lymphocytes called invariant Natural Killer T (iNKT) cells
[8,9]. iNKT cells are a lineage of T lymphocytes that have both innate
and adaptive characteristics and mediate a range of immune responses
[10,11]. NKT cells have a long established role in various disease
conditions such as autoimmunity, cancer, and infectious diseases
[12–16]. iNKT cells express a semi-invariant T cell receptor (TCR) that
responds to glycolipid antigens presented via the non-classical MHC-
like antigen-presenting molecule CD1d [10]. Exogenous lipid antigens
all harbor a sugar headgroup with α stereochemistry, with αGalCer,
originally identified from a screening in extracts of a marine sponge, as
the most potent exogenous ligand [17–19]. Using ceramide as a starting
point, mammalian cells can produce>200 different glycosylcer-
amides. Until recently, mammals were thought to produce glyco-
sylceramides only as β-anomers, but recent studies have challenged this
notion, as the original preparations of β-glycosylceramides contained
minor but highly active fractions of α-glycosylceramides. Several α-
glycosylceramides (α-GalCer, α-GluCer) were detected in mammalian
antigen-presenting cells (APCs), including dendritic cells (DC) and
primary thymocytes [20–23].
iNKT cells are present in high numbers in human and mouse lean AT
whereas obese adipose tissue shows a decrease in iNKT cell numbers
[24–32]. In the absence of external stimuli, AT-resident iNKT cells ex-
hibit a Th2-biased cytokine profile (e.g. high IL-4 production) as com-
pared to spleen iNKT cells [29,31]. Upon stimulation by lipid antigens
presented by the MHC1-like CD1d protein, AT-resident iNKT cells can
secrete both Th1 cytokines (e.g. IFNγ) and Th2 cytokines (IL-4, IL-13,
IL-10) [2,24–26,29,31,33–35].
Interestingly, recent studies showed that human and mouse adipo-
cytes express CD1d and its loading machinery, and regulate iNKT cell
function by acting as lipid antigen displaying APC [26,29,36]. We and
others have shown that iNKT cell activation by adipocytes is dependent
on CD1d [26,34,36]. When cultured in the presence of adipocytes that
overexpress CD1d, iNKT cells show higher cytokine secretion, whereas
CD1d knockdown in adipocytes results in decreased activation of iNKT
cells. Additionally, these co-culture experiments indicate that adipo-
cytes can produce endogenous lipid antigens [36], but the cellular
pathways for lipid antigen presentation in adipocytes remain to be
defined and endogenous adipocyte lipid antigens have not yet been
identified. Such identification would be highly relevant, as endogenous
adipocyte lipid antigens may help to prevent the development of insulin
resistance by preserving AT-resident iNKT cell numbers and activity
[24,25,29,31]. Candidate endogenous adipocyte lipid antigens however
include glucosylceramides, which originate from ceramide, a lipid
species associated with insulin resistance [5].
Here, we address the role of endogenous lipid presentation by adi-
pocytes through examination of the ceramide pathway consisting of
glucosylceramide synthase, which catalyzes the conversion from cer-
amide to glucosylceramide, and lactosylceramide synthases, which
catalyze the conversion from glucosylceramide to lactosylceramide.
Glucosylceramide synthase is encoded by a single gene called UDP-
glucose ceramide glucosyltransferase (Ugcg). Therefore, we hypothesize
that Ugcg is a rate limiting step in the synthesis of endogenous lipid
antigens [37]. This notion is supported by Ugcg−/− mice, which die in
utero (around E8) [38]. Lactosyl synthase is encoded by two genes, β-
1,4-Galactosyltransferase (B4Galt) 5 and 6, which are part of the B4Galt
family consisting of seven members all of which are responsible for the
production of different oligosaccharides and glycoconjugates [39].
B4Galt5 reportedly being the dominant enzyme in the conversion of
glucosylceramide to lactosylceramide [40], which is substantiated by
the in utero death of B4Galt5−/− mice (around E10.5) whereas
B4Galt6−/− mice show no apparent phenotype [40–42]. By reducing
Ugcg expression levels and inhibiting its activity, we show that this
enzyme regulates lipid self-antigen presentation by adipocytes. Fur-
thermore, by reducing B4Galt5 expression, we show that iNKT cell
activating capacities of adipocytes increase, suggesting a prominent
role for glucosylceramide as a lipid antigen. Ugcg controls endogenous
lipid antigen processing in adipocytes in vivo, inhibition of its function
results in decreased iNKT cell effector function in AT. Taken together,
our data suggest that adipocyte-derived glucosylceramides, an im-
portant class of ceramide metabolites, supporting iNKT cell function in
AT.
2. Materials & methods
2.1. Materials
Dexamethasone and 3-isobutyl-1-methylxanthine (IBMX) were from
Sigma Aldrich. The following antibodies were used: Anti-Ugcg
(SAB2104830) and anti-tubulin (T9026) from Sigma-Aldrich (St Louis,
MO, USA), anti-Fabp4 (sc-18661) from Santa Cruz Biotechnology, anti-
B4Galt6 (SAB2106738), anti-B4Galt5 (SAB2106739) from Sigma
Aldrich. IFNγ ELISA kit was from BD biosciences and IL4 ELISA kit was
from eBiosciences. The Vα14- self-lipid and αGalCer -reactive DN32.D3
iNKT hybridoma was a kind gift of Prof. A. Bendelac [43]. Iminosugar
AMP-DNM was synthesized as described previously [44,45].
2.2. Cell culture and differentiation
The murine 3 T3-L1 cell line (ATCC, Manassas, VA) was cultured in
DMEM Glutamax (Dulbecco) containing 10% bovine serum (Life
Technologies), penicillin and streptomycin (both 100 μg/ml; Life
Technologies). For differentiation, 3 T3-L1 cells were grown to con-
fluence and after 2 days incubated with culture medium containing
dexamethasone (250 nM), IBMX (500 μM) and insulin (170 nM) for
3 days. On day 3, medium was changed for culture medium supple-
mented with insulin (170 nM) and left for 4 days. For Western blot
analyses, differentiated 3 T3-L1 cells were lysed in RIPA lysis buffer
(200mm Tris-HCl, pH 8.0; 0,1% SDS, 1% Triton X-100; 10mm EDTA;
150mm NaCl; 1% sodium deoxycholate containing protease in-
hibitors). Cell lysates were subjected to SDS-PAGE, and transferred to
Immobilon membranes (Millipore). ECL Plus (PerkinElmer Life
Sciences) was used for detection on an ImageQuant LAS 4000 (GE
Lifesciences).
2.3. Lentiviral knockdown of Ugcg
The shRNA constructs for mouse Ugcg, (clone nm_011673.2-
374S1C1) B4Galt5. (clone NM_019835.1-733s1c1), and B4Galt6 (clone
NM_019737.1-3486s1c1) were all provided in pLKO-1 lentiviral vectors
(Sigma-Aldrich) Lentiviral particles were produced in 293 T cells. After
lentiviral infection, 3 T3-L1 pre-adipocytes were maintained on 3 μg/ml
puromycin. Stably transduced cells were used for the adipocyte-iNKT
interaction studies.
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2.4. Sphingolipid quantification of 3 T3-L1 adipocytes by HPLC
Lipids were extracted with the Bligh-Dyer method [46]. A water
lysate was prepared of adipocytes previously grown in a 6-well plate
(200 μl of MQ). Lipids were extracted from 75 to 150 μl of lysate, and
samples were divided in two. One part was subjected to deacylation for
ceramide quantification and the other part was directly derivatized for
free sphingosine base quantification. For plasma 50 μl was analyzed.
Deacylation was performed by use of microwave-assisted hydrolysis in
methanolic NaOH. Next, samples were subjected to derivatization of the
sphingoid bases with o-phthaldialdehyde, and separated by HPLC on a
C18 reverse-phase column with methanol/water phase (84.5% me-
thanol, 15.5% water) and quantified with a fluorescence detector (λ(ex)
340 nm and λ(em) 435 nm). One nmol of C17-sphinganine, a sphin-
golipid species that is not naturally generated in the mammalian cells,
was used for internal calibration.
2.5. RNA isolation and quantitative PCR
One μg of RNA, extracted using TRIzol reagent (Invitrogen), was
used for cDNA synthesis with the superscript first strand synthesis
system (Invitrogen) according to manufacturer's protocol. Gene ex-
pression levels were determined by quantitative real time PCR with the
MyIq cycler (Bio-Rad) using SYBR-green (Bio-Rad) and normalized to
TFIIb or 36B4 expression. Primers for quantitative RT-PCR were de-
signed with free Primer3 software or taken from Harvard primer bank
and are described in Table 1.
2.6. (Pre)adipocyte-iNKT interaction
Scramble shRNA, Ugcg shRNA transduced mouse 3 T3-L1 (pre)adi-
pocytes were co-cultured with 50.000 DN32.D3 hybridoma cells per
well in a 96 wells format. After 24 h of co-culture, the supernatant was
stored at −80 °C until analysis of IFNγ and IL4 cytokine levels. For
Ugcg inhibition assay, 10 μM AMP-DNM, a specific chemical inhibitor
of Ugcg [44,45], was added to the 3T3L-L1 cells on day 2 of the dif-
ferentiation. On day 7 inhibitor was washed away and (pre)adipocytes
were co-cultured with 50.000 DN32.D3 hybridoma cells per well in a 96
wells format (24 h). Cytokine levels were measured with commercially
available ELISA kits.
2.7. Animal study/in vivo inhibition of Ugcg
WT C57BL/6 J mice (8 weeks; Charles River Laboratories) were fed
standard chow until age 9 weeks, and subsequently fed LFD (10 kcal%
fat, Research Diet D12450B) for 9 weeks. In the third week of LFD
feeding, weight-matched groups were fed a LFD with or without 25mg
AMP-DNM/kg bodyweight per day until the end of the study (Research
Diet Services). All mouse study protocols were approved by the Utrecht
University Ethical Committee for Animal Experimentation (protocol
2013.III.06.046) and were in accordance with current Dutch laws on
animal experimentation.
2.8. Isolation of mouse leukocytes and (intracellular) flow cytometry
staining
Murine visceral (epididymal) AT was collected, washed in PBS, and
digested for 45min with collagenase type II (Sigma-Aldrich) and DNAse
I (Roche). Stromal vascular cells (SVCs) were pelleted by centrifuga-
tion, incubated for 20min with NH4Cl erythrocyte lysis buffer, and
passed through a 100-μm cup filter (BD). Simultaneously, spleens were
minced through a 70 μm mesh filter (BD) and collected in NH4Cl lysis
buffer. Subsequently, AT SVCs and spleen cells were washed in FACS
buffer (2% fetal calf serum and 0.1% NaN3 in PBS); preincubated with
10% rat serum in FACS buffer; and stained with mAbs specific for TCRβ,
CD3, CD8, CD4, CD25, and for iNKT cell selection αGalCer-loaded
CD1d tetramers (NIH) were used. Part of the cells were then fixed and
permeabilized using the FixPerm (BD) followed by intracellular staining
for IL-4 (BD), IFNγ (BD), IL-13 (BioLegend) and IL-17 (Affimetrix/
eBioscience). As a negative control, the non -iNKT fraction of SVCs (low
αGalCer-loaded CD1d tetramer and TCRβ staining) was analyzed and
CD25 and intracellular cytokine signals were below those observed in
the untreated iNKT cell population (Supplemental Fig. S1). Cells were
analyzed by flow cytometry with a FacsCanto II (BD) flow cytometer
and FACSDiva (BD) and FlowJo (Tree Star Inc.) software.
2.9. Statistical analyses
Data are routinely presented as means ± s.e.m. Statistical sig-
nificance between two groups was determined using Student's t-tests.
Values of p < 0.05 were considered significant and are indicated by *.
3. Results
3.1. Ugcg regulates lipid self-antigen presentation in adipocytes
Glucosylceramides have been identified as potent iNKT cell self-
antigens in both mouse and human professional antigen presenting cells
[20–22]. The rate-limiting enzyme for the synthesis of all glucosylcer-
amides from ceramide is glucosylceramide synthase, which is encoded
by the gene UDP-glucose ceramide glucosyltransferase (Ugcg; Fig. 1a).
Therefore, we hypothesized that Ugcg may be involved in adipocyte
self-antigen presentation to iNKT cells. To characterize the role of Ugcg
in antigen presentation by adipocytes, we first studied its mRNA ex-
pression pattern during the differentiation of 3 T3-L1 pre-adipocytes to
mature adipocytes. Expression of Ugcg was detected in pre-adipocytes
and did not change significantly during adipogenesis, as analyzed by
quantitative RT-PCR (Fig. 1b).
To investigate the role of Ugcg in lipid self-antigen presentation, we
generated 3 T3-L1 cells with stable shRNA-mediated knockdown of
Ugcg. As depicted in Fig. 1c and d, these cells displayed significantly
reduced Ugcg mRNA and protein levels. Ugcg reduction did not criti-
cally impair the differentiation capacity of 3 T3-L1 cells, as assessed by
expression of the differentiation marker Fabp4 (Fig. 1e). We next
quantified glucosylceramide content of 3 T3-L1 (pre)adipocytes by
HPLC [47]. Ugcg knock down reduced intracellular glucosylceramide
levels significantly when compared to control cells, both in pre-adipo-
cytes and in mature 3 T3-L1 adipocytes (Fig. 1f). The levels of ceramide,
the precursor for all glucosylceramides, were increased moderately by
Ugcg knock down (Fig. 1f). Lactosylceramide concentration was re-
duced in Ugcg knockdown cells, most likely due to the decreased
Table 1
Primers for quantitative RT-PCR.
mUgcg_fw AGGAAGGATGTGCTAGATCAGG
mUgcg_rev TTTGCATGGCAACTTGAGTAGA
m36B4_ fw ATGGGTACAAGCGCGTCCTG
m36B4_ rev GCCTTGACCTTTTCAGTAAG
mTFIIb_ fw GTTCTGCTCCAACCTTTGCCT
mTFIIb rev TGTGTAGCTGCCATCTGCACTT
mMCP1_fw CTTCTGGGCCTGCTGTTCA
mMCP1_rev CCAGCCTACTCATTGGGATCA
mIL6_fw CATCCAGTTGCCTTCTTGGG
mIL6_rev CCAGTTTGGTAGCATCCATC
mIL6_fw CTTCCATCCAGTTGCCTTCTTG
mIL6_rev AATTAAGCCTCCGACTTGTGAAG
mTNFα_Fw CAACCTCCTCTCTGCCGTCAA
mTNFα_rev TGACTCCAAAGTAGACCTGCCC
mF4/80_Fw CTTTGGCTATGGGCTTCCAGTC
mF4/80_rev GCAAGGAGGACAGAGTTTATCGTG
mB4Galt5_fw ACTTGGATTGGGATTGTCTGAT
mB4Galt5_rev CGCAGAGTAGTTCAGGTTGTTG
mB4Galt6_fw TATGTCATCGAACAGACCGGCACA
mB4Galt6_rev AGGCTCTGTCTTTCATGGCCTCTT
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Fig. 1. Ugcg regulates lipid self-antigen presentation in adipocytes. (a) Schematic representation of glucosylceramide and lactosyl ceramide synthesis and its in-
hibition by the Ugcg inhibitor AMP-DNM. The focus of this figure is boxed. (b) Mouse 3 T3-L1 preadipocytes were differentiated into mature adipocytes and RNA
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concentration of glycosylceramides (Fig. 1f). Aditionally, the ratio be-
tween glycosylceramide and ceramide was greatly reduced in the Ugcg
knockdown (pre)adipocytes (Fig. 1f).
To address the relevance of Ugcg in lipid antigen presentation, we
made use of a recently developed co-culture system in which 3 T3-L1
(pre)adipocytes are cultured with the mouse iNKT DN32D3 hybridoma
cell line for 24 h, and the production of IFNγ and IL-4 by the iNKT cells
is assessed [36]. This setting has been used previously to show that
iNKT cell activation is CD1d dependent [26,36]. In this setting, cyto-
kine release is observed in the absence of exogenously added lipid an-
tigens, suggesting CD1d mediated presentation of lipid self-antigens by
mature 3 T3-L1 adipocytes [36]. As shown in Fig. 1g, Ugcg knockdown
resulted in a significant reduction of IFNγ and IL4 cytokine release by
DN32D3 iNKT cells. Treatment of adipocytes with the synthetic Ugcg
inhibitor AMP-DNM [44] also significantly decreases the glucosylcer-
amide concentration (Fig. 1h). Inhibiting Ugcg with AMP-DNM resulted
in a significant reduction of IFNγ and IL4 release by iNKT cells (Fig. 1i).
This inhibition of iNKT cell activity required functional lipid antigen
presentation machinery, as AMP-DNM treatment of 3 T3-L1 pre-adi-
pocytes, which are CD1d negative and incapable of lipid antigen pre-
sentation [26,36], had no effect (data not shown). In agreement with
the Ugcg knockdown experiments (Fig. 1e), Ugcg inhibition by AMP-
DNM did not influence the differentiation potential of the pre-adipo-
cytes, as assessed by Fabp4 expression (Fig. 1j). Taken together, these
data qualify glucosylceramide synthesis by Ugcg as a critical step in
adipocyte lipid self-antigen presentation to iNKT cells.
3.2. Inhibition of B4Galt5 and -6 results in higher iNKT cell activation
To further address the importance of Ugcg in iNKT cell activation by
adipocytes, we focused on the next enzymatic step that converts glu-
cosylceramides into lactosylceramides (Fig. 2a). Two enzymes are re-
ported to be responsible for this conversion: β-1,4-Galactosyltransferase
(B4Galt) 5 and B4Galt6 [41,42]. We hypothesize that the inhibition of
B4Galt5 and 6 increases the DN32D3 iNKT cell activating capacity of
3 T3-L1 adipocytes due to a higher availability of glucosylceramides.
To investigate the consequences of decreased B4Galt5 and 6 ex-
pression we used a similar approach to the Ugcg experiments described
above. B4Galt6 was assessed first due to the non-lethal effects in
knockout mice [40]. We checked the mRNA expression of B4Galt6
during differentiation of 3 T3-L1 pre-adipocytes to mature adipocytes.
B4Galt6 expression shows a slight increase during differentiation, as
analyzed by RT-PCR (Fig. 2b). An shRNA mediated B4Galt6 knockdown
3 T3-L1 cell line was created and was confirmed by Western blot
(Fig. 2c). The reduced expression of B4Galt6 also has no effect on
adipogenesis as shown by the expression differentiation marker Fabp4
(Fig. 2d).
The knockdown of B4Galt6 did not result in a significant decrease of
lactosylceramides in mature adipocytes (Fig. 2e). Also, the ratio be-
tween lactosylceramides and glycosylceramides was not decreased in
B4Galt6 knockdown cells (Fig. 2e). This indicates that B4Galt6 does not
play a dominant role in determining total cellular lactosylceramide
levels. Additionally, ceramide and glycosylceramide levels and ratios
were not significantly altered (Fig. 2e). Nevertheless, B4Galt6 knock
down did result in reduced secretion of IL-4 and IFNγ by DN32D3 iNKT
cells (Fig. 2f), suggesting that B4Galt6 has a role in iNKT cell activation
by adipocytes.
To assess if reducing B4Galt5 expression has a similar effect, as
reducing B4Galt6, we knocked down B4Galt5 using shRNA in 3 T3-L1
adipocytes. Firstly, natural B4Galt5 mRNA expression detected in pre-
adipocytes by RT-PCR shows a slight increase during differentiation
(Fig. 2g). The shRNA mediated B4Galt5 knockdown 3 T3-L1 cell line
supported reduced expression of B4Galt5 by Western blot (Fig. 2h). As
observed with the B4Galt6 knockdown, adipogenesis is not altered by
the reduced expression of B4Galt5 as shown by the expression of dif-
ferentiation marker Fabp4 (Fig. 2i). Next, we analyzed the lacto-
sylceramide concentration in B4Galt5 knockdown cells by HPLC. In
contrast to B4Galt6 knock down (Fig. 2f), a significant decrease of
lactosylceramide production was detected in (pre)adipocytes lacking
B4Galt5 compared to a shRNA scrambled cell line (Fig. 2j). Also, the
ratio between lactosylceramides and glycosylceramides in the B4Galt5
knockdown cells was significantly decreased. This difference was ab-
sent in the B4Galt6 knockdown cells. Ceramide and glycosylceramide
content in B4Galt5 knockdown cells also differed compared to shRNA
scrambled cells (Fig. 2j). Additionally, co-culture experiments with
DN32D3 iNKT hybridoma's and 3 T3-L1 mature adipocytes showed that
cytokine secretion measured by ELISA (Il-4 and IFNγ) increases when
B4Galt5 expression is decreased (Fig. 2k).
Taken together, these data suggest a dominant role for B4Galt5
compared to B4Galt6 in the conversion of glucosylceramide to lacto-
cylceramide in adipocytes. However, inhibition of either enzyme re-
sulted in increased cytokine production, suggesting that they play non-
redundant roles in iNKT cell activation. These data stress the im-
portance of the ceramide pathway enzymes in CD1d-dependent acti-
vation of iNKT cells.
3.3. Ugcg inhibition by AMP-DNM in vivo
To address the role of Ugcg on AT iNKT cell numbers and cytokine
production in vivo, mice were treated with the synthetic inhibitor AMP-
DNM for 6 weeks. The inhibitory effect of AMP-DNM on glucosylcer-
amide synthesis was confirmed by blood plasma analysis, showing
significantly reduced levels of glucosylceramide and increased levels of
ceramide (Fig. 3a). Regrettably, glycosylceramide measurements in AT
could not be performed due to high concentrations of TG causing in-
terference in the analytical procedure [45]. Weight gain and food in-
take were not affected by the AMP-DNM treatment (Fig. 3b and c, re-
spectively). In addition, no significant changes were observed in the
expression of several inflammatory genes and the macrophage markers
F4/80 in adipose tissue (Fig. 3d).
samples were taken at different time points during differentiation. Ugcg mRNA levels were analyzed by quantitative RT-PCR. Data are presented as mean ± S.E.
(n=3). Expression levels were normalized for housekeeping gene TFIIB, mean expression at Day 0 was set at 1. (c) 3 T3-L1 preadipocytes were subjected to shRNA-
mediated knockdown of Ugcg by lentiviral transduction and Ugcg mRNA expression was analyzed by quantitative RT-PCR. Data are presented as mean ± S.E.
(n=3). Expression levels were normalized for housekeeping gene TFIIB, mean expression in scramble shRNA 3 T3-L1 adipocytes was set at 1. (d, e) Cell lysates of
differentiated shRNA Ugcg transduced cells and scramble cells were subjected to Western blot analysis using antibodies against Ugcg, FABP4 and tubulin. (f)
Lactosylceramides, glucosylceramides and ceramide levels in shUgcg transduced and scramble 3T3L1 (pre)adipocytes was determined by HPLC analysis of or-
thophtaldehyde-conjugated lipids. Additionally glucosylceramide ceramide ratios in scramble and shUgcg are depicted. (g) iNKT cells were co-cultured with scramble
3 T3-L1 (pre)adipocytes and shRNA Ugcg transduced adipocytes (24 h). The levels of IFNγ and IL4 in the supernatant were measured by ELISA. A representative
experiment is shown with data presented as mean (n= 8). (h) Ugcg inhibitor (AMP-DNM; 10 μM) or DMSO was added to the 3T3L-L1 cells on day 2 of differentiation.
On day 7 inhibitor was washed away and 3 T3-L1 (pre)adipocytes were co-cultured with DN32.D3 hybridoma cells (24 h). The levels of IFNγ and IL4 in the
supernatant were measured by ELISA. A representative experiment is shown with data presented as mean ± S.E. (n= 8). (i) Cell lysates of 3 T3-L1 (pre)adipocytes
treated with AMP-DNM (10 μM) or DMSO were subjected to Western blot analysis using antibodies against FABP4 and tubulin. (j) glucosylceramides – ceramide ratio
in mature 3 t3-L1 adipocytes with and without treatment of AMP-DNM.
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Fig. 2. Inhibition of B4Galt5 and B4Galt6, results in higher iNKT cell activating capacities of adipocytes (a) Schematic representation of glucosylceramide and
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As systemic AMP-DNM treatment may not only inhibit endogenous
lipid antigen presentation in adipose tissue, but also by APCs elsewhere
in the body, we examined the percentage of iNKT cells within the TCRβ
positive population in the spleen. No significant changes were observed
upon AMP-DNM treatment (Fig. 3e), suggesting that there are no gen-
eral systemic effects on iNKT cells after Ugcg inhibition.
3.4. Inhibition of endogenous glucosylceramide production results in
decreased iNKT cell effector function in adipose tissue
Having established that Ugcg inhibition by AMP-DNM effectively
reduced glycosylceramide levels (Fig. 3a) without affecting splenic
iNKT cell numbers (Fig. 3e), the effect of Ugcg inhibition on the relative
numbers and activity of iNKT cells in adipose tissue was addressed. No
significant changes in number of iNKT cells were detected between the
AMP-DNM treated and untreated mice (Fig. 4a and b). However, after a
6-week diet containing AMP-DNM mice displayed markedly reduced
numbers of CD25+ iNKT cells, indicating decreased iNKT cell activity
in AT (Fig. 4a and b). To characterize the phenotype of the AT-resident
iNKT cells upon Ugcg inhibition in more detail, cytokine production by
AT-resident iNKT cells was analyzed. As shown in Fig. 4 c and d, AT
derived iNKT cells from AMP-DNM treated animals produced sig-
nificantly less pro-inflammatory (IFNγ, IL-17) and anti-inflammatory
cytokines (IL-4, IL-13) compared to iNKT cells from control animals.
iNKT cell activity and proliferation can also (co)regulated by other
signals, including inhibition by the adipokine leptin [48]. Previously,
Van Eijk et al. reported improved insulin sensitivity upon AMP-DNM
treatment in leptin-deficient ob/ob mice [47], indicating that inhibition
of Ugcg activity can act independent of leptin. Here, we observed lower
leptin levels upon AMP-DNM treatment, which makes it unlikely that
the drug-induced lowering of iNKT cell activity occurs through leptin
(data not shown). Taken together, these findings indicate that inhibi-
tion of endogenous glucosylceramide production results in decreased
iNKT cells activity and overall cytokine production and underscores the
major role of this enzymatic pathway in lipid self-antigens presentation
by adipocytes.
4. Discussion
Multiple studies in various cellular and animal models have shown
that accumulation of ceramide and ceramide metabolites, including
glucosylceramides, in obesity results in insulin resistance [5,49,50]. For
example, inhibition of Ugcg, the enzyme that catalyzes the first step in
the biosynthesis of glucosylceramides, results in reduced ceramide
metabolite levels (e.g. GM2 and GM3), improved insulin signaling in
adipocytes, and improved whole body insulin sensitivity in several ro-
dent models of obesity [45,47]. Here, we show that the glucosylcer-
amide synthesis pathway is also involved in a different aspect of adi-
pose tissue function. Inhibition of Ugcg in adipocytes results in
decreased iNKT cell action. Both in vitro and in vivo iNKT cell cytokine
production is reduced upon Ugcg inhibition (Figs. 1 and 4). As gluco-
sylceramides have been implicated as endogenous iNKT cell ligands
[51], Ugcg inhibition may well reduce ligand availability and thereby
decrease iNKT cell action. Co-culture studies with CD1d-proficient
adipocytes and iNKT cells support this hypothesis, as Ugcg inhibition in
adipocytes decreased iNKT cell cytokine production, while Ugcg in-
hibition of CD1d-deficient pre-adipocytes did not affect iNKT cell
function. (Fig. 1 and data not shown). As lipid rafts contain multiple
glycosylated lipids [52] and lipid rafts have been associated with CD1d
functioning [53,50], it seems possible that inhibition of CD1d-mediated
lipid antigen presentation occurs indirectly by interfering with lipid raft
integrity. However, Lu et al. recentlty showed that lipid raft disruption
in 3 T3-L1 (pre)adipocytes results in increased MCP-1 production [55],
while we observed no changes in MCP-1 levels upon AMP-DNM treat-
ment in AT (Fig. 3d). Therefore, the decrease of iNKT cell activity upon
Ugcg inhibition is most likely due to impaired lipid antigen production
and unrelated to lipid raft disruption.
Furthermore, assessment of the next step in the biosynthesis
pathway – the conversion of glucosylceramide into lactocylceramide –
shows that iNKT cell cytokine secretion increases upon tinhibition of
B4Galt5 and -6 (Fig. 2). Interestingly, while both enzymes can catalyze
the same reaction, our data suggest that their activities in adipocytes
are not identical: i) B4Galt5 plays a larger role in determining total
cellular lactocylceramide levels than B4Galt6, and ii) inhibition of ei-
ther enzyme resulted in increased iNKT cell activation, indicating that
their activities are not redundant. While the biochemical basis for these
differences remains to be established, our data support a role for glu-
cosylceramide-to-lactocylceramide conversion in iNKT cell activation.
The blockade of lactosylceramide production may possibly improve
ligand availability increasing the iNKT cell activating capacity of adi-
pocytes. These data underscore the role of adipocytes as lipid antigen-
presenting cells, driving adipose tissue immune homeostasis through
modulating iNKT cell responses [26,29,34–36].
As we, and others have suggested a role for iNKT cells in the pre-
vention of insulin resistance [24,25,29,31,34], inhibition of the gluco-
sylceramide biosynthesis pathway, which we show in the present study
to result in altered iNKT cell activity, may be predicted to impair insulin
sensitivity. We did not observe a significant impact on insulin sensi-
tivity in our lean animals upon AMP-DNM treatment ([47] and data not
shown). An important difference between the previous and the present
study lies in the experimental set-up. Data showing the protective role
of iNKT cells was largely obtained from experiments in genetic CD1d−/
− and Jα18−/− knockout models, while a short term (6 weeks) partial
inhibition of a key enzyme in adult mice was performed in the present
study. It is therefore possible that more effective inhibition of Ugcg (i.e.
higher dose or prolonged treatment) would not only inhibit iNKT cell
activity as observed here but would eventually also lead to reduced AT-
resident iNKT cell numbers and result in insulin resistance. It should
lactosyl ceramide synthesis and its inhibition by the Ugcg inhibitor AMP-DNM. The focus of this figure is boxed. (b) Mouse 3 T3-L1 preadipocytes were differentiated
into mature adipocytes, and RNA samples were taken at different time points during differentiation, B4Galt6 mRNA levels were analyzed by quantitative RT-PCR.
Data are presented as mean ± S.E. (n= 3). Expression levels were normalized for housekeeping gene TFIIB, mean expression at Day 0 was set at 1. (c, d) Cell lysates
of differentiated shRNA B4Galt6 transduced cells and scramble cells were subjected to Western blot analysis using antibodies against B4Galt6, FABP4 and tubulin. (e)
Lactosylceramide, glucosylceramide and ceramide concentration in shRNA B4Galt6 and scramble 3 T3-L1 (pre)adipocytes was determined by HPLC analysis of
orthophtaldehyde-conjugated lipids. Additionally lactosylceramide/glucosylceramide ratio in shRNA B4Galt6 and scramble 3 T3-L1 (pre)adipocytes. (f) iNKT cells
were co-cultured with scramble 3 T3-L1 (pre)adipocytes and shRNA B4Galt6 transduced adipocytes (24 h). The levels of IFNγ and IL4 in the supernatant were
measured by ELISA. A representative experiment is shown with data presented as mean (n= 4). (g) Mouse 3 T3-L1 preadipocytes were differentiated into mature
adipocytes, and RNA samples were taken at different time points during differentiation, B4Galt6 mRNA levels were analyzed by quantitative RT-PCR. Data are
presented as mean ± S.E. (n= 3). Expression levels were normalized for housekeeping gene TFIIB, mean expression at Day 0 was set at 1. (h, i) Cell lysates of
differentiated shRNA Ugcg transduced cells and scramble cells were subjected to Western blot analysis using antibodies against B4Galt5, FABP4 and tubulin. (j)
Lactosylceramide, glucosylceramide and ceramide concentration in shRNA B4Galt5 and scramble 3 T3-L1 (pre)adipocytes was determined by HPLC analysis of
orthophtaldehyde-conjugated lipids. Additionally lactosylceramide/glucosylceramide ratio in shRNA B4Galt5 and scramble 3 T3-L1 (pre)adipocytes. (k) iNKT cells
were co-cultured with scramble 3 T3-L1 (pre)adipocytes and shRNA B4Galt5 transduced adipocytes (24 h). The levels of IFNγ and IL4 in the supernatant were
measured by ELISA. A representative experiment is shown with data presented as mean (n=4).
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however be noted that inhibition of glucosylceramide biosynthesis can
improve insulin sensitivity by decreasing adipose tissue inflammation
and improving adipocyte function, at least in obese animals [45,47].
Moreover, ceramide metabolites are key players in multiple im-
munometabolic pathways, which makes it difficult to predict their net
effect on whole body insulin sensitivity [6,56]. For example, ceramide
itself may play a dual role, antagonizing insulin action in the short-
term, but in the long-term its anti-anabolic effects may contribute to
improved glucose tolerance [49]. It is therefore possible that potential
insulin-desensitizing effects of glucosylceramide biosynthesis inhibition
(e.g. impaired iNKT cell activity) are counterbalanced by insulin-sen-
sitizing effects (e.g. improved adipocyte function), resulting in a minor
net effect on whole body insulin sensitivity under our experimental
conditions.
Unraveling Ugcg function may be key to untangling the metabolic
effects of iNKT cells, ceramide and glucosylceramides, which appear to
be intertwined. Ugcg is considered the only genomic glucosylceramide
synthase producing glucosylceramides, and as such is a pivotal enzyme
in glycosphingolipid metabolism [6,37]. While Ugcg exclusively func-
tions as an inverting glucosyltransferase, i.e. transferring glucose to
ceramide in a β-anomeric linkage, α-glucosylceramides are naturally
occurring in mammalian milk and serum as well [20,21]. Recent studies
suggest that these α-linked glycolipids, although present in low con-
centrations, serve as the main endogenous lipid antigens for iNKT cells
in thymus and periphery [20]. The essential role of α-linked glycolipids
is supported by the NKT cell hyperstimulation phenotype observed in
patients with α-galactosidase (GLA) deficiency, also known as Fabry
disease. The catabolic enzyme GLA controls degradation of α-linked
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glycolipids, and its absence in Fabry disease is associated with in-
creased amounts of self-ligands at the surface of antigen-presenting
cells in thymus and periphery [57], resulting in an altered iNKT phe-
notype and ultimately reduced iNKT cell numbers [57,58]. These
findings indicate that the delicate balance between the various enzymes
in the biosynthetic pathway needs to be maintained for proper iNKT
cell development, proliferation and survival. Deciphering the biosyn-
thetic origin of these α-linked glycolipids seems key to unravel the
metabolic effects of endogenous lipid antigens on iNKT cells. Finally,
delineating endogenous lipid antigen processing, including environ-
mental cues that potentially inhibit or stimulate this pathway, or in-
fluence the specific identity of antigens that are being presented, may
reveal novel therapeutic options not only for obesity-induced type 2
diabetes, but also other disorders in which iNKT cells have been im-
plicated [59].
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbalip.2019.04.016.
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